Background: Anti-melanoma differentiation-associated gene 5 (MDA5) antibody identifies a distinct subtype of juvenile dermatomyositis (JDM), typically amyopathic or hypomyopathic and strongly associated with interstitial lung disease (ILD). Neuromyelitis optica spectrum disorder (NMOSD) is an antibody-mediated disorder of the central nervous system associated with aquaporin-4 immunoglobulin G (AQP4-IgG). The coexistence of anti-MDA5 dermatomyositis and AQP4-IgG-positive NMOSD is exceptionally rare, particularly in children.
Case Presentation: A previously well 6-year-old boy developed fever, migratory polyarthritis, an abdominal rash, photosensitive facial papules, and elbow nodules following an upper respiratory illness. He was initially treated with antibiotics for presumed post-streptococcal reactive arthritis. Three weeks later, he developed severe neck pain and rapidly progressive asymmetric paraparesis, becoming unable to walk. Neurological examination demonstrated bilateral pyramidal signs and lower-limb weakness. Cerebrospinal fluid showed mild pleocytosis and elevated protein, with negative microbiological investigations. Creatine kinase exceeded 39,000 IU/L, while ferritin was normal. Anti-MDA5 antibody and AQP4-IgG were positive, with negative MOG-IgG. Magnetic resonance imaging demonstrated longitudinally extensive transverse myelitis extending from the medulla oblongata to T2, with cord expansion and oedema. Whole-body magnetic resonance imaging showed diffuse myositis. High-resolution computed tomography of the chest demonstrated bilateral peripheral ground-glass opacities and nodules with an organising-pneumonia pattern, consistent with ILD. JDM was diagnosed according to the 2017 EULAR/ACR classification criteria, while AQP4-IgG positivity, acute myelitis, and exclusion of alternative diagnoses established NMOSD according to the 2015 consensus criteria. He was treated with intravenous methylprednisolone, intravenous immunoglobulin, mycophenolate mofetil, hydroxychloroquine, and oral prednisolone. Follow-up imaging at eight weeks demonstrated marked improvement of the spinal cord lesion and near-complete resolution of muscle abnormalities.
Conclusion: This case represents an exceptionally rare overlap of anti-MDA5 JDM and AQP4-IgG-positive NMOSD in a young child and, to our knowledge, the youngest reported patient with this overlap. Unlike the commonly recognised amyopathic or hypomyopathic phenotype of anti-MDA5 JDM, this patient had severe biochemical and radiological myositis with creatine kinase exceeding 39,000 IU/L. The presence of ILD further highlights the multisystem severity of anti-MDA5 disease. Normal ferritin did not exclude severe disease. New neurological manifestations in children with inflammatory myopathy should prompt urgent neuraxis imaging and AQP4/MOG antibody testing to identify potentially treatable NMOSD.

